Literature DB >> 29704215

Population Pharmacokinetic Modeling to Describe the Total Plasma and Free Brain Levels of Fluconazole in Healthy and Cryptococcus neoformans Infected Rats: How Does the Infection Impact the Drug's Levels on Biophase?

Izabel Almeida Alves1, Keli Jaqueline Staudt2, Fernando Olinto Carreño1, Graziela de Araujo Lock1, Carolina de Miranda Silva1, Stela Maris Kuze Rates1, Teresa Dalla Costa1, Bibiana Verlindo De Araujo3,4.   

Abstract

PURPOSE: The present work aimed to evaluate the influence of experimental meningitis caused by C. neoformans on total plasma and free brain concentrations of fluconazole (FLC) in Wistar rats.
METHOD: The infection was induced by the administration of 100 μL of inoculum (1.105 CFU) through the tail vein. Free drug in the brain was assessed by microdialisys (μD). Blood and μD samples were collected at pre-determined time points up to 12 h after intravenous administration of FLC (20 mg/kg) to healthy and infected rats. The concentration-time profiles were analyzed by non-compartmental and population pharmacokinetics approaches.
RESULTS: A two-compartmental popPK model was able to simultaneously describe plasma and free drug concentrations in the brain for both groups investigated. Analysis of plasma and μD samples showed a better FLC distribution on the brain of infected than healthy animals (1.04 ± 0.31 vs 0.69 ± 0.14, respectively). The probability of target attainment was calculated by Monte Carlo simulations based on the developed popPK model for 125 mg/kg dose for rats and 400-2000 mg for humans.
CONCLUSIONS: FLC showed a limited use in monotherapy to the treatment of criptoccocosis in rats and humans to value of MIC >8 μg/mL.

Entities:  

Keywords:  Cryptococcus neoformans; fluconazole; infection; meningitis; microdialysis; monte Carlo simulations; poppk model

Mesh:

Substances:

Year:  2018        PMID: 29704215     DOI: 10.1007/s11095-018-2402-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  32 in total

1.  Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial.

Authors:  R A Larsen; M A Leal; L S Chan
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

2.  Increased permeability of blood-brain barrier is mediated by serine protease during Cryptococcus meningitis.

Authors:  Chi-Yu Xu; Hong-Mei Zhu; Jian-Hua Wu; Hai Wen; Cui-Jie Liu
Journal:  J Int Med Res       Date:  2014-01-07       Impact factor: 1.671

3.  Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier.

Authors:  Yun C Chang; Monique F Stins; Michael J McCaffery; Georgina F Miller; Dan R Pare; Tapen Dam; Maneesh Paul-Satyaseela; Kwang Sik Kim; Kyung J Kwon-Chung; Maneesh Paul-Satyasee
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 4.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

Review 5.  Adaptation of Candida albicans to the host environment: the role of morphogenesis in virulence and survival in mammalian hosts.

Authors:  Luigina Romani; Francesco Bistoni; Paolo Puccetti
Journal:  Curr Opin Microbiol       Date:  2003-08       Impact factor: 7.934

6.  Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis.

Authors:  Eric Milefchik; Mary Ann Leal; Richard Haubrich; Samuel A Bozzette; Jeremiah G Tilles; John M Leedom; J Allen McCutchan; Robert A Larsen
Journal:  Med Mycol       Date:  2008-06       Impact factor: 4.076

7.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

Review 8.  Cryptococcal meningitis: epidemiology and therapeutic options.

Authors:  Derek J Sloan; Victoria Parris
Journal:  Clin Epidemiol       Date:  2014-05-13       Impact factor: 4.790

Review 9.  Treatment of cryptococcal meningitis in resource limited settings.

Authors:  Derek J Sloan; Martin J Dedicoat; David G Lalloo
Journal:  Curr Opin Infect Dis       Date:  2009-10       Impact factor: 4.915

Review 10.  Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.

Authors:  Angela Loyse; Françoise Dromer; Jeremy Day; Olivier Lortholary; Thomas S Harrison
Journal:  J Antimicrob Chemother       Date:  2013-06-20       Impact factor: 5.790

View more
  1 in total

1.  Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model.

Authors:  Supavit Chesdachai; Radha Rajasingham; Melanie R Nicol; David B Meya; Felix Bongomin; Mahsa Abassi; Caleb Skipper; Richard Kwizera; Joshua Rhein; David R Boulware
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.